News Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-26 EDT			5-day change	1st Jan Change
5.2 ^USD	-2.80%		-2.80%	+10.64%

04-10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI
03-27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	04-10	CI
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024	04-10	AQ
Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	03-27	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	03-26	MT
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	03-26	AQ
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051	03-14	CI
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million	03-11	AQ
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	03-11	AQ
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	03-11	CI
Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insiders	03-10	CI
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024	03-05	AQ
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor	02-06	AQ
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024	01-30	AQ
Sector Update: Health Care Stocks Stronger Late Afternoon	01-26	MT
Aprea Therapeutics Files $150 Million Mixed Shelf; Shares Fall	01-26	MT
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	01-04	AQ
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	01-04	CI
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Summary

Filters